Stefan Schreiber

ORCID: 0000-0002-6807-9822 · 3 papers in corpus · active 2021-2025

Study types

  • article 3
article 2025
Impact of moderate-to-severe ulcerative colitis and Crohn’s disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) survey
·doi:10.1080/03007995.2025.2530736

BACKGROUND: Ulcerative colitis (UC) and Crohn's disease (CD) negatively affect patients' quality-of-life, and their impact on patients' sexual health is rarely addressed. This study assessed the impact of moderate-to-severe UC and CD on sex…

article 2022
P209 Etrasimod improves quality of life in adults with moderate-to-severe ulcerative colitis
·doi:10.1136/gutjnl-2022-bsg.263

Introduction Active ulcerative colitis (UC) can significantly impact quality of life (QOL). Etrasimod (ETR) is a once-daily, oral, selective sphingosine 1–phosphate receptor 1, 4, and 5 modulator that demonstrated efficacy in inducing respo…

article 2021
S714 Etrasimod Improves Quality of Life in Adults With Moderate-to-Severe Ulcerative Colitis: Results From the Phase 2 OASIS Trial and Open-Label Extension
·doi:10.14309/01.ajg.0000776388.09359.02

Introduction: Active ulcerative colitis (UC) can significantly impact quality of life. Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor 1, 4, and 5 modulator that demonstrated efficacy in inducing response and remis…